Abstract Number: 0588 • ACR Convergence 2023
Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry
Background/Purpose: Rituximab (RTX) is increasingly being employed to treat refractory systemic lupus erythematosus(SLE). Though the drug is effective there is a high risk of adverse…Abstract Number: 1324 • ACR Convergence 2023
Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…Abstract Number: 1856 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project
Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…Abstract Number: 2309 • ACR Convergence 2023
Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with epithelial defects and disrupted intestinal barrier, risking bacterial translocation, and promoting systemic inflammation, known as dysbiosis, which…Abstract Number: 0204 • ACR Convergence 2023
Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases
Background/Purpose: Literature data on the increased risk of severe infection regarding hypogammaglobinemia related to RTX in IMID are controversial and sparse. We proposed to evaluate…Abstract Number: 0663 • ACR Convergence 2023
Vaccine-Preventable Diseases in Hospitalized Patients with Systemic Sclerosis: A Nationwide Cohort Analysis
Background/Purpose: Connective tissue disorders, including systemic sclerosis (SSc), are associated with an increased risk of infections. Infections are the most common diagnosis during hospitalizations and…Abstract Number: 1334 • ACR Convergence 2023
Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses
Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…Abstract Number: 1928 • ACR Convergence 2023
Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies
Background/Purpose: Vaccination against SARS-CoV2 has been the primary global strategy to prevent severe forms of this respiratory infection. However, multiple studies have shown that patients…Abstract Number: 2312 • ACR Convergence 2023
Fungal Infections in Hospitalized Patients of Systemic Lupus Erythematosus: A Nationwide Cohort Analysis
Background/Purpose: Immunosuppressive therapy is the cornerstone of management in patients with systemic lupus erythematosus (SLE). Patients on immunosuppressive therapy are at increased risk of developing…Abstract Number: 0205 • ACR Convergence 2023
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…Abstract Number: 0680 • ACR Convergence 2023
Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study
Background/Purpose: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) is a risk factor for hypogammaglobulinemia. Aggregating data on the kinetics of gammaglobulin levels…Abstract Number: 1445 • ACR Convergence 2023
SLESIS-R: An Improved Score for Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus Based on the RELESSER Prospective Cohort
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of serious infections that varies with the severity of the disease, use of immunosuppressives,…Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…Abstract Number: 2316 • ACR Convergence 2023
Effect of SARS-CoV2 Infection on Disease Flares in Patients with Systemic Lupus Erythematosus: A Case-control Study
Background/Purpose: To study the effect of SARS-CoV2 infection on disease flares in patients with systemic lupus erythematosus (SLE).Methods: Patients who fulfilled the ACR or SLICC…Abstract Number: 0206 • ACR Convergence 2023
Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis
Background/Purpose: Due to the use of immunosuppressants, patients with rheumatic diseases are at increased risk for Hepatitis B virus (HBV) reactivation. B-cell depleting agents and…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 32
- Next Page »